期刊文献+

慢性粒细胞性白血病急变期的细胞遗传学研究 被引量:3

Cytogenetic study of CML at blast crisis
暂未订购
导出
摘要 目的 探讨白血病患者细胞遗传学改变和预后关系。方法 通过短期培养法和直接法对 3 0例慢性粒细胞白血病急变期患者的骨髓有核细胞进行染色分析。结果  3 0例病人Ph染色体均为阳性 ,同时 2 8例出现了染色体数目异常。结论 出现额外染色体畸变时 ,提示临床治疗效果差 ,预后不良 ,生存期短 ,易急变。慢粒急变时 。 Objective To study the relationship beween cytogenetic change and the prognosin in patients with CML acute nonlymphoblastic leukemia.Methods The karyotype analysis of nuclear cells of bone marrow in 30 cases at acute stage were performed by short culture and direct preparation.Results 30 cases were positive with Ph chromosome,meantime 28 cases had chromosome number abnormality.Conclusion When patients with CML have other chromosome abnormalities at the chronic stage,It suggest patients with CML are at acute stage.These cytogenetic abnormalities happened in chronic stage showed the worst prognosis.
出处 《哈尔滨医科大学学报》 CAS 2000年第1期36-38,共3页 Journal of Harbin Medical University
关键词 白血病 染色体 慢性 急变期 粒细胞性 leukemia acute stage chromosome
  • 相关文献

参考文献4

二级参考文献1

  • 1夏海龙,中华血液学杂志,1992年,13卷,531页

共引文献12

同被引文献19

  • 1王立升,于海侠,郭鑫,肖军海,李松.抗Gleevec(STI-571)耐受的Bcr-Abl蛋白酪氨酸激酶抑制剂研究进展[J].广西大学学报(自然科学版),2006,31(1):10-14. 被引量:2
  • 2Laura VM.Chronic myelogenous leukemia:elements of conventional chemotherapy and an overview of Autografting in the treatment of the chronic phase[J].Med Oncol,2003,20(2):95~116
  • 3Hagemeijer A,Bartram CR,Smit EM,et al.Is the chromosomal region 9q34 always involved in variants of the Ph1 translocation?[J].Cancer Genet Cytogenet,1984,13 (1):1 ~ 16
  • 4O'BRIEN SG, GUILHOT F, LARSON RA, et al. Imatinib com- pared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [ J ]. N Engl J Med, 2003,348(11) :994 - 1004.
  • 5DRUKER BJ, GUILHOT F, O'BRIEN SG, et al. Five-yearfol- low-up of patients receiving imatinib for chronicmyeloid leukemia [J]. NEnglJMed, 2006,355(23) :2408 -2417.
  • 6PUTTINI M, COLUCCIA AM,BOSCHELLI F,et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against ima- tlnib-resistant Bcr-Abl + neoplastic cells [ J ]. Cancer Res,2006, 66(23) :11314-11322.
  • 7GOLAS JM, ARNDT K, ETIENNE C, et al. SKI-606, a 4-anili- no-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic nayelogcnous leu- kemia cells in culture and causes regression of K562 xenografts in nude mice [ J ]. Cancer Res,2003,63 ( 2 ) : 375 - 381.
  • 8REDAELLI S, PIAZZA R, ROSTAGNO R, et al. Activity of bo- sutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants[ J]. J Clin Oncol,2009,27(3) :469 -471.
  • 9GAMBACORTI-PASSERINI C, LE COUTRE P, MOLOGNI L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis[ J]. Blood Cells Mol Dis, 1997,23 ( 3 ) :380 - 394.
  • 10FDA. Bosutinib [ EB/OL]. ( 2012 - 09 - 04 ). http ://www. ac- cessdata, fda. gov/drugsatfda_docs/label/2012/203341 lbl. pdf.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部